Endo announced the launch of Natesto (testosterone nasal gel), the first nasal gel for testosterone replacement therapy in adults with hypogonadism. It is indicated for males with congenital or acquired primary hypogonadism or hypogonadotropic hypogonadism.
Natesto is an androgen responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. Effects include the growth and maturation of the prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as facial, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening, alterations in body musculature, and fat distribution.
Natesto is supplied as a metered-dose pump containing 11g of gel dispensed as 60 actuations. Each pump delivers 5.5mg of testosterone in 0.122g of gel.
For more information call (800) 462-3636 or visit Natesto.com.